Revenue Isn’t the Signal: What Early-Stage Health Tech Investors Should Be Watching InsteadApril 21, 2026
Kailera Plans IPO for Obesity Drug That Could Top Lilly’s ZepboundNews DeskMarch 30, 20260 Kailera Therapeutics isn’t the only company developing an obesity drug that hits multiple targets for weight loss, but the clinical-stage…